Long-term outcomes after thiotepa-based high-dose therapy (HDT) and autologous hematopoietic cell transplantation (auto-HCT) in non-Hodgkin lymphoma (NHL). Bone Marrow Transplant 2017 Feb;52(2):321-322
Date
11/29/2016Pubmed ID
27892948DOI
10.1038/bmt.2016.275Scopus ID
2-s2.0-84997822155 (requires institutional sign-in at Scopus site) 2 CitationsAuthor List
Shah N, Rauenzahn S, Veltri L, Wen S, Craig M, Hamadani M, Kanate AS, Cumpston AAuthor
Mehdi H. Hamadani MD Professor in the Medicine department at Medical College of WisconsinMESH terms used to index this publication - Major topics in bold
AdultAged
Autografts
Female
Follow-Up Studies
Hematopoietic Stem Cell Transplantation
Humans
Lymphoma, Non-Hodgkin
Male
Middle Aged
Retrospective Studies
Thiotepa
Time Factors